Stay updated on Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.

Latest updates to the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedVersion 35, submitted on 2026-03-16, adds updates to Study Status and Contacts/Locations and updates the record revision to v3.5.0.SummaryDifference0.4%

- Check23 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check44 days agoChange DetectedVersion 34 updates the record by renaming the study to include Placebo With ADT and adding the Contacts/Locations, Study Design, Study Status, and Study Identification sections. These changes align the study's identification with the protocol and provide essential administrative details for tracking.SummaryDifference0.5%

- Check51 days agoChange DetectedAdded Revision: v3.4.2 to the history. Removed the government funding lapse notice and operating-status guidance that previously appeared on the page.SummaryDifference0.5%

- Check58 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the NIH Clinical Center's status. Updated the page revision to v3.4.1, with the previous revision v3.4.0 removed.SummaryDifference0.5%

- Check65 days agoChange DetectedThe page now shows a Show glossary option and a legend for color-coded changes (green for additions, red for deletions). It also introduces the latest revision label (Revision: v3.4.0) and a minor capitalization change in 'No FEAR Act Data'.SummaryDifference0.7%

Stay in the know with updates to Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.